Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic
25 sept. 2024 07h00 HE
|
Genespire
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the largest private Italian Biotech company financings...
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic
25 sept. 2024 01h00 HE
|
Genespire
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the largest private Italian Biotech company financings...
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
12 sept. 2024 07h00 HE
|
Genespire
PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12...
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer
12 sept. 2024 01h00 HE
|
Genespire
PRESS RELEASE Genespire appoints Karen Aiach-Pignet as Chief Executive Officer Karen’s appointment bolsters Genespire’s position as a leader in in-vivo lentiviral gene therapy Milan, Italy, 12...
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
19 nov. 2020 08h00 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the...
LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients
10 août 2020 06h35 HE
|
LogicBio Therapeutics
– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform – – Enrollment to Start with Patients as Young as 3 Years Old, De-escalating...
LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
10 août 2020 06h30 HE
|
LogicBio Therapeutics
LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with...
LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the American Society of Gene & Cell Therapy 2020 Annual Meeting
11 mai 2020 16h10 HE
|
LogicBio Therapeutics
LEXINGTON, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare...
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
10 janv. 2020 07h05 HE
|
LogicBio Therapeutics
– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients –– Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 –– Established research collaboration with...
Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
15 mai 2017 08h00 HE
|
Selecta Biosciences
Proof of Concept for Rare Disease Methymalonic Acidemia (MMA) Gene TherapyGene Therapy Dose Titration Enabled via SVP-Rapamycin Combination Treatment WATERTOWN, Mass., May 15, 2017 (GLOBE NEWSWIRE)...